17 November 2017; pdfCompany Announcement – Pro Medicus Signs Yale – Acrobat pdf 83k

Highlights

  • 7 year deal with Yale New Haven Health in the US.
  • Estimated value to PME in excess of AUD $18M.
  • Visage 7 to be implemented across Yale’s radiology departments and enterprise-wide for clinical access to imaging results.
  • Transaction-based model with potential upside.
  • Consolidates PME in the US academic radiology space.

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging, Inc., has signed an AUD $18 million, 7 year contract with Yale New Haven Health (“Yale”), affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale is one of the leading, most respected academic institutions in the US.

The contract, based on a transaction licensing model, will see Pro Medicus’ Visage® 7 technology implemented across all of Yale’s radiology departments and integrated to their EHR for imaging results.

The implementation will span five hospitals — Bridgeport, Greenwich, Lawrence+Memorial, Westerly, and Yale New Haven hospitals, including Yale New Haven’s Children Hospital and Smilow Cancer Hospital at Yale New Haven, as well as numerous additional imaging locations across the state of Connecticut. Yale New Haven Hospital is the primary teaching hospital of the Yale School of Medicine.

The first locations are scheduled to go live early in the second half of FY2018 with the remainder to be rolled out over a six month period.

“This is another very significant contract for us,” said Dr Sam Hupert, Pro Medicus CEO. “Yale is one of the top academic institutions in the US and its’ medical school is renowned. Their decision further validates our belief that Visage 7 is uniquely positioned to cater to the needs of the most sophisticated and demanding clinical environments.”

Dr Hupert continued, “This is another major milestone for us in terms of market acceptance and we look to build on this as a basis for continued growth in North American and other global markets.”